Literature DB >> 10958795

Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.

T U Ha1, D L Segev, D Barbie, P T Masiakos, T T Tran, D Dombkowski, M Glander, T R Clarke, H K Lorenzo, P K Donahoe, S Maheswaran.   

Abstract

Müllerian inhibiting substance (MIS), a transforming growth factor-beta family member, causes regression of the Müllerian duct in male embryos. MIS overexpression in transgenic mice ablates the ovary, and MIS inhibits the growth of ovarian cancer cell lines in vitro, suggesting a key role for this hormone in postnatal development of the ovary. This report describes a mechanism for MIS-mediated growth inhibition in both a human epithelial ovarian cancer cell line and a cell line derived from normal ovarian surface epithelium, which is the origin of human epithelial ovarian cancers. MIS-treated cells accumulated in the G(1) phase of the cell cycle and subsequently underwent apoptosis. MIS up-regulated the cyclin-dependent kinase inhibitor p16 through an MIS type II receptor-mediated mechanism and inhibited growth in the absence of detectable or inactive Rb protein. Prolonged treatment with MIS down-regulated the Rb-related protein p130 and increased the Rb family-regulated transcription factor E2F1, overexpression of which inhibited growth. These findings demonstrate that p16 is required for MIS-mediated growth inhibition in ovarian epithelial cells and tumor cells and suggest that up-regulation of E2F1 also plays a role in this process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958795     DOI: 10.1074/jbc.M005701200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

2.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

3.  CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

Authors:  Alba Rodriguez-Garcia; Prannda Sharma; Mathilde Poussin; Alina C Boesteanu; Nicholas G Minutolo; Sarah B Gitto; Dalia K Omran; Matthew K Robinson; Gregory P Adams; Fiona Simpkins; Daniel J Powell
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

4.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

Authors:  Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2011-05-13       Impact factor: 5.650

7.  Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.

Authors:  Jae Yen Song; Hyun Hee Jo; Mee Ran Kim; Young Oak Lew; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; Patricia K Donahoe; David T MacLaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2012-02-14       Impact factor: 5.650

8.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

9.  The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.

Authors:  Pradeep S Tanwar; Arno E Commandeur; LiHua Zhang; Makoto M Taketo; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2012-09-07       Impact factor: 4.944

10.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.